Get API key
Reporting owner · Q3 2026 · CIK 1518611

Sibold William John: insider trades.

Sibold William John reported 35 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 34 sales ($7.6M), across 1 company.

Transactions
35
Purchases (P)
0
Sales (S)
34
Companies
1
Name as filed
Sibold William John

Companies

CompanyRelationshipTransactions
Madrigal Pharmaceuticals, Inc. (MDGL)Director, Officer · President and CEO35

Transactions

35 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-09-11Madrigal Pharmaceuticals, Inc.S60$533.09202,907Form 4
2026-09-11Madrigal Pharmaceuticals, Inc.S218$535.94202,583Form 4
2026-09-11Madrigal Pharmaceuticals, Inc.S160$537.62202,423Form 4
2026-09-11Madrigal Pharmaceuticals, Inc.S687$540.59201,736Form 4
2026-09-11Madrigal Pharmaceuticals, Inc.S368$541.64201,368Form 4
2026-09-11Madrigal Pharmaceuticals, Inc.S1,202$542.6200,166Form 4
2026-09-11Madrigal Pharmaceuticals, Inc.S1,539$544.02198,627Form 4
2026-09-11Madrigal Pharmaceuticals, Inc.S761$544.83197,866Form 4
2026-09-11Madrigal Pharmaceuticals, Inc.S120$546.38197,746Form 4
2026-09-11Madrigal Pharmaceuticals, Inc.S106$534.06202,801Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S160$542.55202,967Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S131$527.88209,198Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S347$529.27208,851Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S522$530.23208,329Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S368$531.99207,961Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S512$533.09207,449Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S396$534.2207,053Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S644$535.27206,409Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S1,040$536.11205,369Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S640$537.17204,729Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S520$538.3204,209Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S215$539.03203,994Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S505$540.19203,489Form 4
2026-09-09Madrigal Pharmaceuticals, Inc.S362$541.65203,127Form 4
2026-07-20Madrigal Pharmaceuticals, Inc.S545$544.71211,034Form 4
2026-07-20Madrigal Pharmaceuticals, Inc.S280$555.05209,329Form 4
2026-07-20Madrigal Pharmaceuticals, Inc.S1$550.72209,609Form 4
2026-07-20Madrigal Pharmaceuticals, Inc.S153$550.01209,610Form 4
2026-07-20Madrigal Pharmaceuticals, Inc.S47$548.87209,763Form 4
2026-07-20Madrigal Pharmaceuticals, Inc.S680$547.7209,810Form 4
2026-07-20Madrigal Pharmaceuticals, Inc.S269$547.08210,490Form 4
2026-07-20Madrigal Pharmaceuticals, Inc.S275$545.71210,759Form 4
2026-07-20Madrigal Pharmaceuticals, Inc.S110$543.79211,579Form 4
2026-07-20Madrigal Pharmaceuticals, Inc.S140$542.75211,689Form 4
2026-07-17Madrigal Pharmaceuticals, Inc.M50,000—211,829Form 4

Questions

What stock did Sibold William John buy or sell?

Sibold William John reported 35 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 34 sales ($7.6M), across 1 company.

Is Sibold William John the same person as other filers with this name?

This page covers SEC CIK 1518611 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/sibold-william-john-1518611.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.